Key Takeaways
- Silo Pharma shares climbed 47.55% during after-hours trading Monday, reaching $0.52
- The European Patent Office delivered a Rule 71(3) communication indicating plans to approve a patent for its preventative PTSD treatment
- The patent encompasses methods utilizing serotonin 4 (5-HT4) receptor agonists for preventing stress-related fear and depressive symptoms
- Columbia University exclusively licenses the patent to Silo Pharma, with anticipated coverage throughout key European territories
- SILO maintains a market capitalization around $4.98 million, trading significantly beneath its 52-week peak of $1.18
Silo Pharma received promising news Monday when the European Patent Office (EPO) delivered a Rule 71(3) communication — a formal indication that patent approval is forthcoming — for its innovative preventative approach to PTSD treatment.
The patent filing, designated “Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress,” focuses on the serotonin 4 (5-HT4) receptor mechanism. This methodology centers on blocking stress-induced fear responses and depressive-type behaviors at their source, utilizing a preventative framework.
Columbia University holds the original rights and has granted exclusive licensing to Silo Pharma. The company currently assesses options for Unitary Patent protection alongside national validations throughout European territories to maximize geographic reach.
CEO Eric Weisblum characterized the development as a “high-value milestone” that reinforces the firm’s worldwide intellectual property standing.
Patent Scope and Application
The approved claims detail specific methods for preventing stress-triggered fear responses, depressive-like manifestations, and associated affective conditions through select 5-HT4 receptor agonists.
This represents a distinct strategy compared to conventional PTSD interventions, which address symptoms following their emergence. Silo’s methodology aims at establishing stress resilience proactively.
The patent provides direct support to SPC-15, the company’s primary PTSD development candidate. Silo’s complete development portfolio features SP-26 for fibromyalgia and chronic pain management, alongside early-stage candidates addressing Alzheimer’s disease.
Stock Performance Analysis
SILO concluded Monday’s standard trading session at $0.36 before jumping to $0.52 during after-hours activity — representing a 47.55% increase.
The share price’s 52-week trajectory provides broader context: the stock reached $1.18 at its apex and descended to $0.22 at its lowest point during the past year. These fluctuations reflect substantial volatility for a company valued near $5 million.
Benzinga’s equity assessments indicated SILO demonstrated unfavorable price momentum across all measured timeframes prior to Monday’s announcement.
The after-hours rally pushed shares above the $0.50 threshold for the first time in recent sessions, although the price remains well below the 52-week maximum.
Once the EPO formally issues the grant, Silo’s PTSD therapy is anticipated to receive protection throughout principal European commercial markets.
